XENETIC BIOSCIENCES, INC. Research and Development in Process
XENETIC BIOSCIENCES, INC. (XBIO) reported Research and Development in Process of $1.30 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2022-11-09
- XENETIC BIOSCIENCES, INC. research and development in process for the quarter ending 2022-09-30 was $0.00.
- XENETIC BIOSCIENCES, INC. research and development in process for the quarter ending 2021-09-30 was $0.00.
- XENETIC BIOSCIENCES, INC. research and development in process for fiscal 2012 was $1.09M.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.30M 10-Q · filed 2022-11-09 | ||
| 2022-06-30 | $1.30M 10-Q · filed 2022-08-11 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-11 | |||
| 2020-09-30 | $0.00 10-Q · filed 2020-11-12 | |||
| 2019-09-30 | $3.03M 10-Q · filed 2020-11-12 | |||
| 2012-12-31 | $1.09M 10-K · filed 2015-07-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |